Analysts expect Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) to announce sales of $3.60 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Adaptimmune Therapeutics’ earnings. The highest sales estimate is $7.00 million and the lowest is $200,000.00. Adaptimmune Therapeutics posted sales of $1.48 million during the same quarter last year, which would indicate a positive year over year growth rate of 143.2%. The firm is scheduled to issue its next earnings results on Wednesday, February 26th.
On average, analysts expect that Adaptimmune Therapeutics will report full year sales of $4.00 million for the current financial year, with estimates ranging from $600,000.00 to $7.40 million. For the next year, analysts expect that the company will report sales of $29.05 million, with estimates ranging from $6.00 million to $52.10 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Adaptimmune Therapeutics.
Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its earnings results on Wednesday, November 6th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.03). The business had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $7.00 million.
Adaptimmune Therapeutics stock traded down $0.11 during trading hours on Monday, reaching $3.92. 1,940,311 shares of the company were exchanged, compared to its average volume of 4,876,342. The firm has a market cap of $410.39 million, a price-to-earnings ratio of -2.82 and a beta of 1.83. The company has a current ratio of 3.93, a quick ratio of 3.93 and a debt-to-equity ratio of 0.15. The stock has a 50-day moving average of $1.98 and a 200 day moving average of $1.76. Adaptimmune Therapeutics has a 12 month low of $0.71 and a 12 month high of $6.00.
In other news, Director James Noble sold 300,000 shares of the stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $4.67, for a total value of $1,401,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders sold 317,323 shares of company stock valued at $1,447,506 over the last three months. 22.36% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Millennium Management LLC boosted its position in shares of Adaptimmune Therapeutics by 5.2% in the third quarter. Millennium Management LLC now owns 914,416 shares of the biotechnology company’s stock valued at $1,380,000 after acquiring an additional 45,249 shares during the period. Man Group plc raised its stake in shares of Adaptimmune Therapeutics by 11.4% in the third quarter. Man Group plc now owns 2,049,668 shares of the biotechnology company’s stock valued at $3,095,000 after purchasing an additional 210,443 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Adaptimmune Therapeutics by 21,372.0% in the third quarter. Tower Research Capital LLC TRC now owns 21,472 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 21,372 shares in the last quarter. Finally, Bamco Inc. NY raised its stake in shares of Adaptimmune Therapeutics by 6.1% in the second quarter. Bamco Inc. NY now owns 172,669 shares of the biotechnology company’s stock valued at $694,000 after purchasing an additional 10,000 shares in the last quarter. 65.06% of the stock is owned by institutional investors.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.
Featured Article: What is Cost of Debt?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.